Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

NCT ID: NCT03267498

Last Updated: 2026-01-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-02-14
• Study Completion Date: 2024-10-31

Brief Summary

This phase II trial studies how well nivolumab and chemoradiotherapy works in treating patients with stage II-IVB nasopharyngeal cancer. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells. Chemoradiotherapy is the combination of chemotherapy and radiation therapy and may prevent the cancer from spreading when combined with nivolumab. Giving nivolumab and chemoradiotherapy may work better in treating patients with stage II-IVB nasopharyngeal cancer.

Detailed Description

PRIMARY OBJECTIVES:

I. To establish the feasibility of treatment completion of a combined chemoradiation-nivolumab regimen followed by adjuvant nivolumab.

SECONDARY OBJECTIVES:

I. To determine the overall response rate at 1 year from end of treatment, as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.

II. To determine the locoregional control rate at 1 year post-treatment.

III. To determine the distant metastasis rate at 1 year post-treatment.

IV. To determine the rate of Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) clearance at end of chemoradiation and at 1 year from end of treatment.

V. To determine the acute and late toxicity rates according to Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5, including immune-related adverse events (AEs).

VI. To assess patients' quality of life from baseline through 1 year from end of treatment.

EXPLORATORY OBJECTIVES:

I. To determine the overall survival rate at 5-year post-treatment.

II. To determine whether programmed death-ligand 1 (PD-L1) -positive immunohistochemistry and novel quantitative assays correlate to clinical outcome.

III. To determine if the density of infiltrating Cluster of differentiation 3 (CD3)+ T cells/μm2 correlates to clinical outcome.

IV. To monitor immune changes by flow cytometry in the circulating T cell response to EBV antigens.

V. To compare the change in the circulating T-cell repertoire by TCR sequencing and single-cell T-cell profiling.

VI. To quantify treatment-induced changes over time in the circulating T cell immune response to EBV using T-cell receptor (TCR) sequencing and enzyme-linked immunospot (ELISPOT) assays.

OUTLINE:

Patients receive nivolumab intravenously (IV) over 60 minutes on day 1 of courses 1-5 and 7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy once daily (QD) 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1, 3, 6, 9, and 12 months for up to 1 year and then survival follow-up information may be collected via telephone calls, clinic follow-up visits, or medical records review for up to an additional 4 years. Survival and disease status will be collected until participant death, withdrawal, or if the participant is lost to follow-up.

Conditions

Nasopharyngeal Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Nivolumab + chemoradiation

Patients receive nivolumab IV over 60 minutes on day 1 of courses 1-5 and 7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy QD 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

Nivolumab

Intervention Type: DRUG

Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.

Cisplatin

Intervention Type: DRUG

Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.

Radiation Therapy

Intervention Type: RADIATION

2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday

Interventions

Nivolumab

Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.

Intervention Type: DRUG

Cisplatin

Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.

Intervention Type: DRUG

Radiation Therapy

2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday

Intervention Type: RADIATION

Other Intervention Names

Opdivo

Eligibility Criteria

Inclusion Criteria

1. Males and females ≥18 years of age.

2. Histologically or cytologically confirmed nasopharyngeal carcinoma, stage II-IV by American Joint Committee on Cancer (AJCC) 7th edition, endemic-type (defined as World Health Organization (WHO) type 2a and 2b nonkeratinizing or undifferentiated subtypes, excluding WHO type I keratinizing subtype) performed on a biopsy that occurred within 90 days of registration.

3. Positron emission tomography-computed tomography (PET-CT) (preferred) or a CT of chest, abdomen, and pelvis within 60 days of registration showing radiographic stage II to IVB nasopharyngeal cancer.

4. No distant metastasis as verified by one of the study investigators.

5. Documentation that the patient is a candidate for chemoradiation of their nasopharyngeal cancer by one of the study investigators.

6. Ability to tolerate radiation therapy (e.g. lie flat and hold position for treatment).

7. Measurable disease as defined by RECIST v1.1.

8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

9. Lack of contraindications to systemic immunotherapy (see list of exclusions below).

10. Resolution of all acute toxic effects of any prior chemotherapy, radiotherapy or surgical procedures to NCI CTCAE Version 5.0 grade 1.

11. Adequate hepatic, hematologic, and renal indices permitting administration of cisplatin and nivolumab (within 14 days of registration):

Hepatic Function:

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); Total bilirubin ≤ 1.5 × ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)

Adequate bone marrow function:

White blood cells (WBC) ≥ 2000/μL Neutrophils ≥ 1500/μL Platelet ≥ 100 x103/μL Hemoglobin > 9.0 g/dL

Adequate renal function:

Serum creatinine ≤ 1.5 × upper limit of normal (ULN) OR

Creatinine clearance (CrCl) > 40 mL/min (or > 50 mL/min for Singapore sites only) (if using the Cockcroft-Gault formula below):

Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL

12. Women of childbearing potential must have a negative serum pregnancy test within 24 hours prior to the first dose of study treatment and agree to use appropriate highly effective methods of contraception, during the study and for 5 months following completion of study treatment; A "Woman of childbearing potential" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 62 must have a documented serum follicle stimulating hormone (FSH) level less than 40 milli-international units per milliliter (mIU/mL).

Female Subjects:

Women of child bearing potential are expected to use one of the highly effective methods of contraception listed in the protocol.

Male Subjects:

Male subjects must inform their female partners who are women of child bearing potential of the contraceptive requirements and are expected to adhere to using contraception with their partner. Female partners of male subjects, who are women of child bearing potential, are expected to use one of the highly effective methods of contraception listed in the protocol. In addition, male subjects are expected to use a condom as noted in the protocol.

13. Men with a female partner of childbearing potential must agree to use highly effective methods of contraception or any contraceptive method with a failure rate of less than 1% per year during the study and for 7 months following completion of study treatment.

14. Ability to sign informed consent.

Exclusion Criteria

1. Active second malignancy, i.e. patient known to have potentially fatal hematologic malignancy or another solid primary tumor present for which he/she may be (but not necessarily) currently receiving treatment. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are allowed to enroll in this trial. For example, patients with early-stage skin cancers, prostate cancer under surveillance with non-rising prostate-specific antigen (PSA), or meningioma or thyroid papillary cancers which are under surveillance are eligible. For determinations of a specific clinical condition, please consult with the Principal Investigator.

2. Active, untreated central nervous system (CNS) metastases;

3. Prior treatment with any other anti-programmed cell death protein-1 (anti-PD-1), or PD Ligand-1 (PD-L1) or PD Ligand-2 (PD-L2), anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways, or cancer vaccine;

4. Prior systemic cytotoxic therapy, antineoplastic biologic therapy, or major surgery within 28 days of first dose of study medication;

5. Severe hypersensitivity reaction to treatment during prior administration of a monoclonal antibody (mAb) or history of allergy to any study drug component;

6. Has received a live-virus vaccination within 30 days of planned treatment start;

7. Condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.

8. Any evidence of current interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or pneumonitis requiring oral or IV glucocorticoids;

9. Active, known, or suspected autoimmune disease or any autoimmune condition that has required systemic treatment in the past 2 years (replacement therapies for hormone deficiencies are allowed); Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.

10. Clinically active diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction, or abdominal carcinomatosis (known risks factors for bowel perforation);

11. Signs or symptoms of infection within 2 weeks prior to first day of study treatment.

12. Patients with active tuberculosis (clinical evaluation in line with local practice), or a known history of active tuberculosis that in the opinion of the treating investigator has a high risk of reactivation.

13. Received therapeutic oral or IV antibiotics within 2 weeks prior to first day of study treatment: Patients receiving prophylactic antibiotics (eg, to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible.

14. Known positive test for human immunodeficiency virus (HIV);

15. Known active hepatitis B or hepatitis C virus (HBV or HCV): Patients with past or resolved HBV infection (defined by a negative hepatitis B surface antigen (HBsAg) test and a positive anti-hepatitis B core antigen (HBc) (anti-HBc)antibody test) are eligible. HBV DNA must be obtained in these patients prior to first day of study treatment. Patients who have been recently discovered to have HBV with positive HBsAg test and positive anti-HBc antibody test but who have been started on antiretroviral treatment with nondetectable HBV DNA are eligible. HBV DNA must be obtained in these patients prior to first day of study treatment

16. Patients with known active hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection: Patients positive for HCV antibody are eligible only if Polymerase chain reaction (PCR) test is negative for HCV RNA.

17. Prior radiation therapy of any type within 7 days of first dose of study medication;

18. Prior radiation therapy to head and neck region that would overlap with intended radiation treatment for nasopharyngeal carcinoma;

19. Medical contraindication to radiation treatment (e.g. active systemic sclerosis, other uncontrolled autoimmune condition)

20. Treatment with prohibited medications (including concurrent anticancer therapy including chemotherapy, radiation, hormonal treatment [except corticosteroids and megestrol acetate] ≤ 14 days prior to treatment.

21. Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study;

22. Active, uncontrolled psychiatric disorders or substance (drug/alcohol) abuse that interfere with patient's safety, ability to provide informed consent, or ability to comply with the protocol.

23. Persons who are incarcerated or otherwise under compulsory detention by an authority are not eligible.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National University of Singapore

OTHER

Sponsor Role: collaborator

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: collaborator

Sue Yom

OTHER

Sponsor Role: lead

Responsible Party

Sue Yom

Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Sue S Yom, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Locations

University of California, San Francisco

San Francisco, California, United States

National University Hospital Singapore

Singapore, , Singapore

Countries

United States; Singapore

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

NCI-2017-02291

Identifier Type: OTHER

Identifier Source: secondary_id

162010

Identifier Type: -

Identifier Source: org_study_id